← Home / SPYRE THERAPEUTICS, INC. (SYRE)
Stock Analysis
SPYRE THERAPEUTICS, INC. (SYRE)
SYRE
SYRE · Market data
103.58 +1.70%
Track SYRE in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SYRE price is:
52W Range Position
98%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-16 20:22 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 105.33. Holding above 93.75 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
93.75
↗
Break Above
Confirmation improves above resistance.
105.33
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 93.75
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
4
●
Financial Results
HIGH
SYRE reports financial results
On August 4, 2026, Spyre Therapeutics, Inc.
8-K Filing • SEC EDGAR
JUN
1
●
Material Agreement
MEDIUM
SYRE material agreement
On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended, the "SPY003 License Agreement"), by and between the Company and Paragon Therapeutics, Inc.
8-K Filing • SEC EDGAR
MAY
29
●
Management / Board
MEDIUM
SYRE board and management update
On May 27, 2026, the Company held its Annual Meeting.
8-K Filing • SEC EDGAR
What's Driving SYRE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 105.33 for confirmation and 93.75 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 100.54 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
56.1
Price Chart
SYRE — 1D Chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
≈ Insufficient
📈 Net Income
-36.20M
≈ Insufficient
🧮 EPS (Basic)
1.06
≈ Insufficient
SPYRE THERAPEUTICS, INC.
Related Opportunities